The DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index.
Quantifying the effects of antiangiogenic and chemotherapy drug combinations on drug delivery and treatment efficacy.
Open accessAbstract
Tumor-induced angiogenesis leads to the development of leaky tumor vessels devoid of structural and morphological integrity.Due to angiogenesis, elevated interstitial fluid pressure (IFP) and low blood perfusion emerge as common properties of the tumor microenvironment that act as barriers for drug delivery.In order to overcome these barriers, normalization of vasculature is considered to be a viable option.However, insight is needed into the phenomenon of normalization and in which conditions it can realize its promise.In order to explore the effect of microenvironmental conditions and drug scheduling on normalization benefit, we build a mathematical model that incorporates tumor growth, angiogenesis and IFP.We administer various theoretical combinations of antiangiogenic agents and cytotoxic nanoparticles through heterogeneous vasculature that displays a similar morphology to tumor vasculature.We observe differences in drug extravasation that depend on the scheduling of combined therapy; for concurrent therapy, total drug extravasation is increased but in adjuvant therapy, drugs can penetrate into deeper regions of tumor. Author summaryTumor vessels being very different from their normal counterparts are leaky and lack organization that sustains blood circulation.As a result, insufficient blood supply and high fluid pressure begin to appear inside the tumor which leads to a reduced delivery of drugs within the tumor, especially in tumor center.A treatment strategy that utilizes antivascular drugs is observed to revert these alterations in tumor vessels, making them more normal.This approach is suggested to improve drug delivery by enhancing physical transport of drugs.In this paper, we build a mathematical model to simulate tumor and vessel growth as well as fluid pressure inside the tumor.This framework enables us to simulate drug treatment scenarios on tumors.We use this model to find whether the delivery of the chemotherapy drugs is enhanced by application of anti-vascular drugs by making vessels more normal.Our simulations show that anti-vascular drug not only enhances the
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Antiangiogenic agents are thought to normalize tumor vasculature to allow for better delivery of chemotherapy.”
From Lenvatinib Plus Ifosfamide and Etoposide in Children and Young Adults With Relapsed Osteosarcoma (2024) · cites this paper as [19]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527
Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size
Cabral, H., Matsumoto, Y., Mizuno, K., Chen, Q., Murakami, M., Kimura, M., Terada, Y., Kano, M. R., Miyazono, K., Uesaka, M., et al. (2011) · Nature Nanotechnology · doi:10.1038/nnano.2011.166 · Cited by 2,429
Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
Jain, R. K. (2001) · Nature Medicine · doi:10.1038/nm0901-987 · Cited by 2,184
A Phase 3 Trial of Bevacizumab in Ovarian Cancer
Perren, T. J., Swart, A. M., Pfisterer, J., Ledermann, J. A., Pujade-Lauraine, E., Kristensen, G., Carey, M. S., Beale, P., Cervantes, A., Kurzeder, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103799 · Cited by 2,172
Batchelor, T. T., Sorensen, A. G., di Tomaso, E., Zhang, W.-T., Duda, D. G., Cohen, K. S., Kozak, K. R., Cahill, D. P., Chen, P.-J., Zhu, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.11.021 · Cited by 1,769
Kabbinavar, F., Hurwitz, H. I., Fehrenbacher, L., Meropol, N. J., Novotny, W. F., Lieberman, G., Griffing, S., & Bergsland, E. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.066 · Cited by 1,716
Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases
Carmeliet, P., & Jain, R. K. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3455 · Cited by 1,675
Reck, M., von Pawel, J., Zatloukal, P., Ramlau, R., Gorbounova, V., Hirsh, V., Leighl, N., Mezger, J., Archer, V., Moore, N., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.5466 · Cited by 1,505
Research works printed but not linked: 1
- F Curry, 1984, Mechanics and thermodynamics of transcapillary exchange, Handbook of physiology, 4, 309
Cited by
Tumor Angiogenesis and Anti-Angiogenic Strategies for Cancer Treatment
Teleanu, R. I., Chircov, C., Grumezescu, A. M., & Teleanu, D. M. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm9010084 · Cited by 503
In silico clinical trials: concepts and early adoptions
Pappalardo, F., Russo, G., Tshinanu, F. M., & Viceconti, M. (2019) · Briefings in Bioinformatics · doi:10.1093/bib/bby043 · Cited by 279
Gaspar, N., Venkatramani, R., Hecker-Nolting, S., Melcon, S. G., Locatelli, F., Bautista, F., Longhi, A., Lervat, C., Entz-Werle, N., Casanova, M., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00387-9 · Cited by 89
Lenvatinib Plus Ifosfamide and Etoposide in Children and Young Adults With Relapsed Osteosarcoma
Gaspar, N., Hung, G.-Y., Strauss, S. J., Campbell-Hewson, Q., Dela Cruz, F. S., Glade Bender, J. L., Koh, K.-N., Whittle, S. B., Chan, G. C.-F., Gerber, N. U., et al. (2024) · JAMA Oncology · doi:10.1001/jamaoncol.2024.4381 · Cited by 28
Metadata
- Authors
- Yonucu, S., Yιlmaz, D., Phipps, C., Unlu, M. B., & Kohandel, M.
- Affiliations
- Boğaziçi University (TR)
- University of Waterloo (CA)
- Venue
- PLoS Computational Biology
- Publisher
- Public Library of Science (PLoS)
- Published
- 2017-09-18
- Volume
- 13
- Issue
- 9
- Pages
- e1005724
- ISSN
- 1553-734X (ISSN-L)
- 1553-7358
- PMC
- PMC5633204
- OpenAlex
- W2755804993
- Cited by
- 46
- References
- 72
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 4 · 2023: 4 · 2022: 11 · 2021: 8 · 2020: 6 · 2019: 6 · 2018: 3
- FWCI
- 3.06
- Type
- journal article
- Language
- en
- Update notices
- new_version (2017-10-09)
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS Computational Biology (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- M Curie Reintegration Grant (268287)
- TUBITAK Grant (113F047)
- Topics
- Physical Sciences › Mathematics › Modeling and Simulation › Mathematical Biology Tumor Growth
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- tumor angiogenesis, anti-angiogenic therapy, chemotherapy, drug delivery, interstitial fluid pressure, tumor microenvironment, vascular normalization, drug scheduling, drug extravasation, tumor growth modeling, nanoparticle drug delivery, combination therapy
- MeSH terms
- Antineoplastic Combined Chemotherapy Protocols, Computer Simulation, Dose-Response Relationship, Drug, Drug Therapy, Computer-Assisted, Humans, Models, Biological, Neoplasms, Neovascularization, Pathologic, Treatment Outcome, Tumor Burden
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Quantifying the effects of antiangiogenic and chemotherapy drug combinations on drug delivery and treatment efficacy. https://app.cochat.ai/papers/10.1371/journal.pcbi.1005724
- The paper
- Yonucu, S., Yιlmaz, D., Phipps, C., Unlu, M. B., & Kohandel, M. (2017). Quantifying the effects of antiangiogenic and chemotherapy drug combinations on drug delivery and treatment efficacy. PLoS Computational Biology. https://doi.org/10.1371/journal.pcbi.1005724
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.